2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17490R
    Oxaceprol (Standard) 33996-33-7
    Oxaceprol (Standard) is the analytical standard of Oxaceprol. This product is intended for research and analytical applications. Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.
    Oxaceprol (Standard)
  • HY-17490S
    Oxaceprol-d3 98%
    Oxaceprol-d3 (N-Acetyl-L-hydroxyproline-d3) is deuterium labeled Oxaceprol. Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.
    Oxaceprol-d3
  • HY-17492R
    Zafirlukast (Standard) 107753-78-6
    Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
    Zafirlukast (Standard)
  • HY-17492S
    Zafirlukast-d7 1217174-18-9 98%
    Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
    Zafirlukast-d7
  • HY-17503D
    Metoprolol Hydrochloride 56392-18-8 98%
    Metoprolol Hydrochloride is an orally active and selective β1-adrenoceptor antagonist. Metoprolol Hydrochloride exhibits anti-inflammatory, antitumor, and anti-angiogenic properties.
    Metoprolol Hydrochloride
  • HY-17507R
    Pantoprazole (Standard) 102625-70-7
    Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole (Standard)
  • HY-17569R
    Difluprednate (Standard) 23674-86-4
    Difluprednate (Standard) is the analytical standard of Difluprednate. This product is intended for research and analytical applications. Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.
    Difluprednate (Standard)
  • HY-17582R
    Decloxizine (Standard) 3733-63-9
    Decloxizine (Standard) is the analytical standard of Decloxizine. This product is intended for research and analytical applications. 0
    Decloxizine (Standard)
  • HY-176008
    Lauric acid leelamide 2095306-47-9 98%
    Lauric acid leelamide is the lauric acid (C-12) amide analog of Leelamine (HY-W005629). Leelamine exhibits inhibitory activity against pyruvate dehydrogenase kinase (PDHK) with an IC50 value of 9.5 µM. Leelamine derivatives possess anti-inflammatory effects and can inhibit phospholipase A2 activity from various sources.
    Lauric acid leelamide
  • HY-176029
    N-Oleoyl-DPPE ammonium 98%
    N-Oleoyl-DPPE ammonium is an N-acylphosphatidylethanolamine (NAPE). N-Oleoyl-DPPE ammonium is a biosynthetic precursor of oleoylethanolamide (OEA), an endocannabinoid derivative and peroxisome proliferator-activated receptor α (PPARα) agonist. N-Oleoyl-DPPE ammonium can be used in the study of neuroinflammation and alcohol abuse.
    N-Oleoyl-DPPE ammonium
  • HY-17618R
    Pemafibrate (Standard) 848259-27-8
    Pemafibrate (Standard) is the analytical standard of Pemafibrate. This product is intended for research and analytical applications. Pemafibrate is a highly selective PPARα agonist, with an EC50 of 1 nM.
    Pemafibrate (Standard)
  • HY-17627R
    Avacopan (Standard) 1346623-17-3
    Avacopan (Standard) is the analytical standard of Avacopan. This product is intended for research and analytical applications. Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
    Avacopan (Standard)
  • HY-176466
    ST-899 143484-41-7
    ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock.
    ST-899
  • HY-18054A
    BVT-2733 hydrochloride 376641-65-5 98%
    BVT-2733 hydrochloride is a potent, selective and orally active nonsteroidal 11β-HSD1 inhibitor. BVT-2733 hydrochloride is more potent against mouse 11β-HSD1 enzyme (IC50=96 nM) than against human 11β-HSD1 enzyme (IC50=3341 nM). BVT-2733 hydrochloride has the potential to be used in the study of arthritis and obesity-related diseases.
    BVT-2733 hydrochloride
  • HY-18733S
    Lipoic acid-d4 1448263-85-1 98%
    Lipoic acid-d4 ((R)-(+)-α-Lipoic acid-d4) is deuterium labeled Lipoic acid. Lipoic acid ((R)-(+)-α-Lipoic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. (R)-(+)-α-Lipoic acid is more effective than racemic Lipoic acid.
    Lipoic acid-d4
  • HY-19017B
    Fenclozine dimaleate 76823-82-0 98%
    Fenclozine dimaleate is a non-steroidal antiinflammatory agent.
    Fenclozine dimaleate
  • HY-19151B
    Fuzapladib potassium 141284-74-4 98%
    Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib potassium
  • HY-19344R
    Lifitegrast (Standard) 1025967-78-5
    Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.
    Lifitegrast (Standard)
  • HY-19344S
    Lifitegrast-d4 98%
    Lifitegrast-d4 (SAR 1118-d4) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.
    Lifitegrast-d4
  • HY-19562A
    PF-06260933 hydrochloride 1883548-86-4 98%
    PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
    PF-06260933 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity